[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 1 Issue 10, May 2011].
This NICE clinical guideline has been amended to incorporate the updated NICE technology appraisal of drugs for Alzheimer’s disease, published in March 2011 (NICE technology appraisal of drugs for Alzheimer’s disease). See pages 31–33 for the updated information. The rest of the NICE clinical guideline is unchanged.
Amendments in March / April 2011
The clinical guideline has been amended to incorporate the updated NICE technology appraisal of drugs for Alzheimer’s disease, published in March 2011.
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has changed parts of the guidance. Specifically:
- Donepezil, Galantamine and Rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and
- Memantine is now recommended as an option for managing moderate Alzheimer’s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer’s disease.
This guideline makes recommendations on Alzheimer’s disease, dementia with Lewy bodies (DLB), frontotemporal dementia, vascular dementia and mixed dementias, in addition to recommendations that apply to all types of dementia.
This newly updated Guideline, (updated in March/April 2011), covers:
- Person-centred care.
- Key priorities for implementation.
- Principles of care for people with dementia.
- Integrated health and social care.
- Risk factors, prevention and early identification.
- Diagnosis and assessment of dementia.
- Promoting and maintaining independence of people with dementia.
- Interventions for cognitive symptoms and maintenance of function for people with dementia. (Updated).
- Interventions for non-cognitive symptoms and behaviour that challenges in people with dementia.
- Interventions for comorbid emotional disorders in people with dementia.
- Inpatient dementia services.
- Palliative care, pain relief and care at the end of life for people with dementia.
- Support and interventions for the carers of people with dementia.
- Notes on the scope of the guidance.
- Research recommendations.
- Other versions of this guideline.
- Full guideline.
- Quick reference guide.
- Understanding NICE guidance.
- Related NICE and SCIE guidance.
- Updating the guideline.
- Appendix A: The Guideline Development Group.
- Appendix B: The Guideline Review Panel.
There is a set of associated documentation, available from here, which includes:
- Audit support.
- Costing report.
- Costing template.
- Slide set.
- Dementia: implementation advice.
- Dementia: audit support (update).
- Memory assessment service commissioning guide.
- End of life care for people with dementia commissioning guide.
The full .pdf report:
National Collaborating Centre for Mental Health commissioned by the Social Care Institute for Excellence, National Institute for Health and Clinical Excellence (2011). NICE–SCIE Guideline on supporting people with dementia and their carers in health and social care (National Clinical Practice Guideline Number 42). London: NICE, March / April 2011.
Note: Dementia in Parkinson’s Disease has a number of similarities with dementia with Lewy bodies (DLB). While the evidence base for dementia in Parkinson’s Disease is not covered specifically in this guideline, the recommendations for DLB may be useful when considering treatments for dementia in Parkinson’s Disease. NICE has also produced a clinical guideline on Parkinson’s Disease (read more: http://www.nice.org.uk/nicemedia/live/10984/30087/30087.pdf).